Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 18,512 Shares of Stock

Key Points

• Invivyd insider Robert Allen III sold 18,512 shares at an average price of $0.65, reducing his ownership by 18.70% to 80,488 shares.
• The company reported a quarterly earnings loss of ($0.12) per share, missing estimates, with total revenue of $11.79 million compared to a consensus of $23.16 million.
• Wall Street analysts generally maintain a Buy rating for Invivyd, with a consensus target price of $3.85, despite recent price target adjustments.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Robert Allen III sold 18,512 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $0.65, for a total value of $12,032.80. Following the completion of the sale, the insider directly owned 80,488 shares in the company, valued at approximately $52,317.20. This represents a 18.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Invivyd Stock Performance

Shares of IVVD traded down $0.0101 on Tuesday, hitting $0.5710. 1,690,635 shares of the stock traded hands, compared to its average volume of 850,421. The company has a market capitalization of $68.60 million, a PE ratio of -0.62 and a beta of 0.51. The business has a 50 day simple moving average of $0.75 and a 200 day simple moving average of $0.84. Invivyd, Inc. has a one year low of $0.3546 and a one year high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $11.79 million for the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. On average, equities analysts expect that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Invivyd in a research report on Thursday, June 26th. D. Boral Capital lowered their price objective on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $3.85.

Institutional Trading of Invivyd

Several large investors have recently added to or reduced their stakes in IVVD. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the second quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC grew its position in Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after buying an additional 28,146 shares during the period. Jane Street Group LLC grew its position in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after buying an additional 87,358 shares during the period. Barclays PLC grew its position in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after buying an additional 9,207 shares during the period. Finally, Nuveen LLC bought a new stake in Invivyd during the first quarter valued at approximately $65,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.